好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Abulia: A case of Powassan Encephalitis
Infectious Disease
P4 - Poster Session 4 (5:30 PM-6:30 PM)
4-015
To report a case of Powassan Encephalitis presenting with abulia.

Powassan encephalitis is a rare tick born disease caused by a virus from the family Flaviviridae, genus Flavivirus. While the patients can have variable presentations including headache, nausea, confusion, seizures, weakness, coma; mood disorders as a part of the presentation has not been reported. Abulia is a state of diminished motivation characterized by apathy and delayed response to questioning.

Here, we present a 54 year-old female with no past medical history and no known tick exposure who presented to us with a week history of persistent headache, nausea and emesis. Her neurological exam was significant for apathy, anhedonia and slowed responses.

MRI brain with and without contrast showed non-enhancing, white matter FLAIR hyperintense lesions of the frontal lobes bilaterally, largest on the right frontal centrum semiovale. Her CSF analysis was notable for lymphocytic pleocytosis. The screening for Powassan virus with IgM capture enzyme-linked immunosorbent assay came positive both in serum and CSF.

While abulia was not reported as a symptom of Powassan Encephalitis, this case demonstrates an interesting presentation of frontal lobe lesions caused by Powassan resulting in abulia. It is important to recognize that in addition to the classic symptoms of encephalitis, mood problems may also exist in cases with Powassan Encephalitis.
Authors/Disclosures
Nilufer Yalcin, MD
PRESENTER
Dr. Yalcin has nothing to disclose.
Mohammed Al-Dulaimi, MD (Inova Fairfax Hospital) Dr. Al-Dulaimi has nothing to disclose.
No disclosure on file
Doreen Ho, MD (MGH) Dr. Ho has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals.